Adverum Biotechnologies 2017 Gene Therapy Investor Presentation

Adverum Biotechnologies is developing novel gene therapies for rare diseases including wet age-related macular degeneration, alpha-1 antitrypsin deficiency, and hereditary angioedema. The company leverages industry-leading vector development capabilities and clinical expertise to advance its pipeline of three lead programs. As of December 2016, Adverum held $222 million in cash to fund lead programs through 2019.